PainReform (PRFX) Issues Year-End Business Update

Go back to PainReform (PRFX) Issues Year-End Business Update

PainReform Provides Year-End Business Update

March 1, 2024 8:00 AM UTC

Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy

Remains on track to announce top-line data by mid-2024

TEL AVIV, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2023.

Ilan Hadar, Chief... More